Evaluation and management of shock in patients with COVID-19

Posted July 2, 2020

ABSTRACT

Shock is common in critically ill patients with COVID-19, developing in up to 67% of patients in intensive care (5% to 10% overall) and is associated with high mortality. Optimal management requires prompt recognition with precise evaluation and differentiation. Correcting hypoperfusion and treating the underlying process are fundamental aspects of treatment. Undifferentiated shock may be treated initially with norepinephrine to optimize perfusion while additional evaluation is performed to categorize the shock pathophysiology. Physical examination, bedside echocardiography, hemodynamic monitoring, lactate and venous oxygen saturation are important components of the patient evaluation.

INTRODUCTION

Shock is a clinical state of circulatory failure characterized by impaired oxygen delivery or utilization at the cellular level. The basic characteristics of shock usually consist of systemic hypotension (systolic blood pressure < 90 mmHg or mean arterial pressure < 65 mmHg), organ hypoperfusion, and abnormal cellular oxygen metabolism. Between 5% and 10% of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require intensive care unit (ICU) admission with up to 67% developing shock. Shock has been implicated as the primary cause of death in 7% of coronavirus disease 2019 (COVID-19) cases and as a contributing factor in an additional 33%. All 4 types of shock—distributive, cardiogenic, obstructive, and hypovolemic shock—have been observed in patients with COVID-19.

This review discusses the classification and management of shock in patients with COVID-19. The most common aspects of evaluation are detailed in Table 1. The common causes and characteristics of shock are listed in Table 2. Advanced and invasive hemodynamic monitoring techniques may be needed if conventional techniques fail to diagnose the cause of shock or for hemodynamic monitoring. The increased risk of thromboembolic events in this group has to be calculated when considering advance invasive monitoring devices.

DISTRIBUTIVE SHOCK

Septic shock appears to be the predominant cause of distributive shock in patients with COVID-19, secondary to the virus itself or from bacterial co-infections. COVID-19 has also been associated with a hyper-inflammatory immune response with elevated cytokine levels termed cytokine storm or cytokine release syndrome. This syndrome leads to loss of vasomotor tone and higher rates of mortality. The occasional greater need for sedation in severe cases of COVID-19–associated pneumonia may cause hypotension from direct medication effect or blunted sympathetic drive.

There is limited information on the presence of bacterial coinfection with COVID-19–associated pneumonia. Extrapolating data from Middle East respiratory syndrome (MERS) and influenza showing that 18% and 11% of patients developed bacterial co-infection, respectively, may provide support for initiating empiric antibiotics in critically ill COVID-19 patients. It is also prudent to practice antibiotic stewardship by rapidly discontinuing antibiotics if no evidence of bacterial infection is found.

The choice of an empiric regimen should be based on the patient’s clinical history and local microbiological characteristics. Among hospitalized patients with COVID-19 who require supplemental oxygen, current IDSA guidelines recommend a 5-day course of remdesivir. The use of other COVID-19–specific
antimicrobial therapy remains an area of active clinical research and their use in routine clinical practice cannot be recommended at this time point.

The evidence on sepsis and acute respiratory distress syndrome (ARDS) suggests using conservative fluid management over a liberal management strategy. In patients with ARDS, a conservative strategy resulted in increased ventilator-free and ICU-free days with reduced need for renal replacement therapy (RRT) versus a liberal strategy. If needed, balanced crystalloids are the preferred resuscitative fluid owing to its potential reno-protective effect, which reduces the need for RRT as well as providing a possible mortality benefit. Other evidence suggests use of dynamic indices for fluid responsiveness (eg, pulse pressure variation, systolic pressure variation, passive leg raise, and end-expiratory occlusion tests) over static measures (eg, central venous pressure). A strategy of fluid resuscitation based on preload responsiveness has shown improved outcomes with reduced need for RRT and mechanical ventilation.

Norepinephrine remains the preferred vasopressor agent in septic shock. Vasopressin or epinephrine may be added as a second agent if distributive shock remains the predominant component. There is an increasing body of evidence suggesting improved outcomes with early administration of vasopressors.

If there is concern for inadequate cardiac output, an inotropic agent may be added. Stress-dosed steroids are routinely used in septic shock if perfusion remains impaired despite the above resuscitation strategies and may have a role in patients with acute respiratory failure requiring invasive mechanical ventilation.

The current recommendation is to target mean arterial pressure (MAP) goals of 60 to 65 mmHg. An initial goal of MAP above 65 mmHg, which is later individualized based on a dynamic assessment of perfusion using capillary refill time, mentation and urine output, is a reasonable approach.

### CARDIOGENIC SHOCK

The incidence of acute cardiac injury (defined by an elevated troponin level) in patients with COVID-19 ranges from 20% to 30% and is associated with increased mortality. Causes of acute cardiac injury include demand ischemia, myocarditis, stress-induced cardiomyopathy, or less commonly, acute plaque rupture that may present as single or biventricular failure. Severe left ventricular systolic failure has been reported in COVID-19 from myocarditis, ST-elevation myocardial infarction (STEMI) with systolic heart failure and shock, or from worsening of underlying cardiovascular disease. Right ventricle failure may develop from pulmonary embolism or from pulmonary hypertension (ie, acute cor pulmonale) due to hypoxia, hypercapnia, and/or high mean airway pressures.

These patients should be carefully monitored for significant cardiac injury and development or worsening of shock. At this point, repeat echocardiograms, NT-proBNP levels, troponin levels, and focused cardiac ultrasound should be pursued. The clinical and echocardiographic characteristics of cardiogenic shock are presented in Table 2.

Norepinephrine is first-line vasopressor in patients with cardiogenic shock who are hypotensive, albeit with limited data. If the patient continues to have severely reduced cardiac output with signs of organ hypoperfusion, as evident by clinical, laboratory, and echocardiographic examination (cold extremities, low central venous oxygen saturation, left or right ventricle systolic dysfunction on echocardiography), inotropic agents such as dobutamine or epinephrine may be considered.

Right ventricle failure in ARDS is common and under-recognized, with reported incidence rates ranging from 25% to 50%. Development of right ventricle failure from ARDS or injurious ventilator

### TABLE 1

<table>
<thead>
<tr>
<th>Key parameters in the evaluation of shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical examination</strong></td>
</tr>
<tr>
<td>Capillary refill</td>
</tr>
<tr>
<td>Mental status</td>
</tr>
<tr>
<td>Extremity temperature</td>
</tr>
<tr>
<td>Urine output</td>
</tr>
<tr>
<td><strong>Focused echocardiography</strong></td>
</tr>
<tr>
<td>LV systolic function</td>
</tr>
<tr>
<td>RV size and function</td>
</tr>
<tr>
<td>LVOT VTI</td>
</tr>
<tr>
<td>Pericardial effusion</td>
</tr>
<tr>
<td>Mitral, aortic, and tricuspid valve</td>
</tr>
<tr>
<td>Regional wall motion abnormality</td>
</tr>
<tr>
<td><strong>Laboratory studies</strong></td>
</tr>
<tr>
<td>Mixed venous oxygen saturation</td>
</tr>
<tr>
<td>Central venous oxygen saturation</td>
</tr>
<tr>
<td>Lactate</td>
</tr>
</tbody>
</table>

LV = left ventricle; LVOT VTI = left ventricular outflow tract velocity time integral; RV = right ventricle
settings should be managed with “right ventricle protective ventilation,” which primarily involves minimizing airway pressures (optimizing positive end-expiratory pressure [PEEP], driving pressure, plateau pressure) and prone position ventilation.\(^\text{27,28}\) There are physiologic rationales for using inhaled pulmonary vasodilators (eg, epoprostenol or nitric oxide) to reduce pulmonary vascular resistance, augment right ventricle performance, and improve pulmonary ventilation and perfusion (V/Q) matching.\(^\text{29}\)

Refractory cardiogenic shock may prompt consideration of mechanical circulatory support, including veno-arterial extra corporeal life support. A guidance document on use of extracorporeal membrane oxygenation in COVID-19 patients has been published.\(^\text{30}\) This should be discussed by an experienced, multidisciplinary team at a qualified ECMO center.

**OBSERVATIONAL SHOCK**

COVID-19 has been linked to coagulopathy and increased thrombotic risk. The incidence varies from 25% to 50%, with some thrombotic events occurring despite adequate prophylactic or therapeutic anticoagulation.\(^\text{31,32}\) In one study, acute pulmonary embolism (PE) accounted for 81% of all acute thrombotic complications in patients with COVID-19.\(^\text{33}\) In autopsies performed on 12 patients, acute PE was found to be the direct cause of death in 4 patients.\(^\text{34}\)

Acute PE should be suspected in patients with sudden hemodynamic or respiratory deterioration. The presence of acute PE as the cause of shock is an indication for systemic thrombolysis.\(^\text{35}\) Full therapeutic anticoagulation is indicated in the presence of any acute venous thromboembolism.

During the COVID-19 pandemic, many centers have adopted protocols for “enhanced prophylaxis” using higher than normal doses of thromboprophylaxis in patients with elevated D-dimer levels.\(^\text{36,37}\) Based on expert opinion, the Anticoagulation Forum (a North American organization of anticoagulation providers) recommended using high-intensity prophylaxis (eg, enoxaparin 40 mg subcutaneous twice a day) in patients at high risk of thrombotic events.

### TABLE 2

**Common shock etiologies and differentiation strategies**

<table>
<thead>
<tr>
<th>Type of shock</th>
<th>Etiologies</th>
<th>Extremities</th>
<th>Cardiac output</th>
<th>Mixed venous O(_2)</th>
<th>LV systolic function</th>
<th>RV size/function</th>
</tr>
</thead>
</table>
| **Distributive** | Sepsis\(^a\)  
Cytokine storm\(^a\)  
Medication-related vasoplegia  
Anaphylaxis  
Neurogenic | Warm (sometimes cold) | Normal or high | Normal or high | Normal or high | Normal |
| **Cardiogenic** | Pre-existing heart disease  
Acute myocardial ischemia  
Cardiomyopathy  
Acute myocarditis | Cold | Low | Low | Low | Normal or dilated/reduced function |
| | Acute valvular disease | Cold | Low | Low | Normal or hyperdynamic | Variable |
| | Right ventricle failure\(^a\) | Cold | Low | Low | Normal or hyperdynamic | Dilated/reduced function |
| **Obstructive** | Pulmonary embolism\(^a\) | Cold | Low | Low | Normal or hyperdynamic | Dilated/reduced function |
| | Dynamic hyperinflation (auto-PEEP)  
Pericardial tamponade  
Abdominal compartment syndrome  
Pneumothorax\(^a\) | Cold | Low | Low | Normal or hyperdynamic | Normal |
| **Hypovolemic** | Volume depletion  
Hemorrhage | Cold | Low | Low | Normal or hyperdynamic | Normal |

\(LV = \) left ventricle; \(RV = \) right ventricle

\(^a\)Common in COVID-19.
daily, enoxaparin 0.5 mg/kg subcutaneous twice daily, heparin 7500 units subcutaneous three times daily, or low-intensity heparin infusion). However, recently published Chest guidelines recommend standard-dose thromboprophylaxis in critically ill COVID-19 patients due to lack of evidence on the bleeding risks.

Dynamic hyperinflation can be commonly seen in patients with ARDS who are ventilated with high respiratory rates due to inadequate expiratory time. In the setting of high airway resistance, this may lead to dynamic hyperinflation with elevated intrinsic PEEP (or auto PEEP). High airway resistance may occur due to mucous plugging in the airways, including the endotracheal tube. Routine ventilator checks should include assessment of intrinsic PEEP and airway resistance. Other management strategies might include bronchodilators, hypertonic saline, neuromuscular blockade, airway clearance, use of a large (eg, 8.0 mm) endotracheal tube when able, and heated humidity for ventilator circuits. None of these techniques have been prospectively evaluated for efficacy.

Pneumothorax may occur due to injurious airway pressures and is an important diagnosis to consider during acute decompensation. Needle decompression may be considered in acute hemodynamic decompensation setting due to pneumothorax. Management includes tube thoracostomy, typically with a medium bore pigtail catheter.

Finally, although rare, cardiac tamponade has been reported in at least 1 COVID-19 case as a result of a hemorrhagic etiology. As part of a focused cardiac ultrasound, pericardial effusions should be evaluated for hemodynamic significance, bearing in mind that tamponade features on echocardiography need to be correlated with a clinical examination.

**HYPOVOLEMIC SHOCK**

Hypovolemia may be present in earlier stages of hospitalization due to poor oral intake and high-grade fever causing insensible losses, possibly along with associated diarrhea. The benefit of intravenous fluids administration for dehydration should be weighed against concern for worsening pulmonary edema and hypoxemia, further supporting the use of preload responsiveness assessment to guide fluid administration. Bleeding is another potential cause and may occur due to high rates of coagulopathy and associated anticoagulation use.

There are no COVID-19 specific transfusion recommendations; however, a hemoglobin goal of greater than 7.0 mg/dL is appropriate based on prior data for patients with sepsis and critical illness. Additional blood products (fresh frozen plasma, platelets, cryoprecipitate) can be used as appropriate in the setting of coagulopathy and need for massive transfusion.

**OTHER CONSIDERATIONS**

Frequent contact with the patient, though a cornerstone in attentive shock resuscitation, must be minimized in COVID-19 cases to reduce healthcare worker viral exposure and personal protective equipment use. There are several ways to reduce patient contact. Central venous pressure waveforms and pulse pressure variation can be displayed on the patient monitor as additional continuous monitoring variables. Mental status can be assessed through telecommunication. Intravenous pumps can be relocated outside the room with tubing extensions to permit bedside nurses to efficiently titrate vasoactive medications from outside the room. Obtaining central and arterial access early can reduce overall exposure of healthcare workers to the patient. Using a protocolized point-of-care ultrasound can eliminate the need for a consultative complete echocardiogram and associated human and equipment exposure. Nevertheless, direct contact is still required to assess capillary refill and extremity warmth, and it is ideally done when other care is being provided (ie, bundled care).

**SUMMARY**

Shock of a variety of etiologies is common in critically ill patients with COVID-19 and is associated with high mortality. Prompt recognition along with precise evaluation and management are keys to patient care. Correcting hypoperfusion and treatment of the underlying process are the fundamental aspects of management. Undifferentiated shock may be managed initially with norepinephrine to optimize perfusion while urgent evaluation is performed to categorize the shock pathophysiology. Physical examination, bedside echocardiography, hemodynamic monitoring, and central venous oxygen saturation are important components of evaluation. Further studies are needed to clarify whether there are any nuances to COVID-19–associated shock management, particularly with distributive shock, as compared with other shock etiologies.
REFERENCES


Correspondence: Siddharth Dugar, MD, Department of Pulmonary Medicine, Respiratory Institute, L22-0330, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; dugars@ccf.org